RYTM Stock - Rhythm Pharmaceuticals, Inc.
Unlock GoAI Insights for RYTM
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $130.13M | $77.43M | $23.64M | $3.15M | N/A |
| Gross Profit | $116.76M | $68.13M | $21.50M | $2.56M | $-690,000 |
| Gross Margin | 89.7% | 88.0% | 91.0% | 81.0% | N/A |
| Operating Income | $-265,503,000 | $-184,357,000 | $-179,157,000 | $-170,059,000 | $-136,575,000 |
| Net Income | $-260,602,000 | $-184,678,000 | $-181,119,000 | $-69,612,000 | $-130,727,000 |
| Net Margin | -200.3% | -238.5% | -766.2% | -2207.1% | N/A |
| EPS | $-4.34 | $-3.20 | $-3.51 | $-1.37 | $-2.96 |
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Visit WebsiteEarnings History & Surprises
RYTMEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Feb 25, 2026 | $-0.80 | — | — | — |
Q4 2025 | Nov 4, 2025 | $-0.72 | $-0.82 | -13.9% | ✗ MISS |
Q3 2025 | Aug 5, 2025 | $-0.66 | $-0.75 | -13.6% | ✗ MISS |
Q2 2025 | May 7, 2025 | $-0.69 | $-0.81 | -17.4% | ✗ MISS |
Q1 2025 | Feb 26, 2025 | $-0.69 | $-0.72 | -4.3% | ✗ MISS |
Q4 2024 | Nov 5, 2024 | $-0.80 | $-0.73 | +8.8% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $-0.70 | $-0.55 | +21.4% | ✓ BEAT |
Q2 2024 | May 7, 2024 | $-2.34 | $-2.35 | -0.4% | ✗ MISS |
Q1 2024 | Feb 22, 2024 | $-0.70 | $-0.70 | 0.0% | = MET |
Q4 2023 | Nov 7, 2023 | $-0.76 | $-0.76 | 0.0% | = MET |
Q3 2023 | Aug 1, 2023 | $-0.80 | $-0.82 | -2.5% | ✗ MISS |
Q2 2023 | May 2, 2023 | $-0.71 | $-0.92 | -29.6% | ✗ MISS |
Q1 2023 | Mar 1, 2023 | $-0.82 | $-0.75 | +8.5% | ✓ BEAT |
Q4 2022 | Nov 8, 2022 | $-1.01 | $-0.79 | +21.8% | ✓ BEAT |
Q3 2022 | Aug 2, 2022 | $-0.79 | $-0.89 | -12.7% | ✗ MISS |
Q2 2022 | May 3, 2022 | $-0.98 | $-1.05 | -7.1% | ✗ MISS |
Q1 2022 | Mar 1, 2022 | $-1.00 | $-0.85 | +15.0% | ✓ BEAT |
Q4 2021 | Nov 2, 2021 | $-0.84 | $-0.70 | +16.7% | ✓ BEAT |
Q3 2021 | Aug 3, 2021 | $-0.75 | $-0.70 | +6.7% | ✓ BEAT |
Latest News
Frequently Asked Questions about RYTM
What is RYTM's current stock price?
What is the analyst price target for RYTM?
What sector is Rhythm Pharmaceuticals, Inc. in?
What is RYTM's market cap?
Does RYTM pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to RYTM for comparison